

Amarin Corporation plc Investor Relations Department 2 Pembroke House, Upper Pembroke Street 28-32 Duiblin 2 Ireland

Visit IR website ☐ Sign-up for Email alerts ☐ ☐



Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... (more)

Stock Performance



Press Releases [View all]

Apr 23, 2018

Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer

Apr 12, 2018

Amarin Sponsors Three Scientific
Presentations Scheduled for National Lipid
Association Scientific Sessions

Apr 12, 2018

Vascepa® (Icosapent Ethyl) Showed
Reductions in Potentially Atherogenic Lipid
and Inflammatory Markers in Statin-Treated
Patients with Reduced Kidney Function and
Persistent High Triglycerides

Apr 4, 2018

Amarin Updates First Quarter Revenue

Guidance, Reiterates Full Year Guidance and
Updates on REDUCE-IT Cardiovascular

Outcomes Study Progress and Vascepa®

Promotion Initiatives

Apr 4, 2018

Amarin's REDUCE-IT Cardiovascular
Outcomes Study Reaches 100% Mark for
Estimated Onset of Target Primary Major
Adverse Cardiovascular Events

Financials [View all]

Fourth Quarter Financial Results

Feb 27, 2018

Annual Report (10-K)

Apr 20, 2018

Proxy Statement (DEF 14A)

Nov 1, 2017

Quarterly Report (10-Q)

Aug 2, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)